Traders Sell Amicus Therapeutics (FOLD) on Strength Following Insider Selling
Investors sold shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on strength during trading on Tuesday following insider selling activity. $3.03 million flowed into the stock on the tick-up and $32.50 million flowed out of the stock on the tick-down, for a money net flow of $29.47 million out of the stock. Of all companies tracked, Amicus Therapeutics had the 0th highest net out-flow for the day. Amicus Therapeutics traded up $0.12 for the day and closed at $15.16Specifically, CEO John F. Crowley sold 65,581 shares of the stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $13.51, for a total transaction of $885,999.31. Following the completion of the sale, the chief executive officer now owns 393,076 shares in the company, valued at approximately $5,310,456.76. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jay Barth sold 5,000 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.71, for a total value of $73,550.00. Following the sale, the insider now owns 69,184 shares of the company’s stock, valued at approximately $1,017,696.64. The disclosure for this sale can be found here. In the last quarter, insiders have sold 207,870 shares of company stock valued at $3,066,112. Company insiders own 3.40% of the company’s stock.
FOLD has been the subject of a number of research analyst reports. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 19th. BidaskClub lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 13th. Robert W. Baird set a $20.00 target price on Amicus Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Finally, Cowen restated a “buy” rating and issued a $22.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $19.06.
The firm has a market capitalization of $2,520.00, a P/E ratio of -18.05 and a beta of 1.59. The company has a current ratio of 5.60, a quick ratio of 5.53 and a debt-to-equity ratio of 0.47.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Great West Life Assurance Co. Can raised its stake in shares of Amicus Therapeutics by 40.2% during the 3rd quarter. Great West Life Assurance Co. Can now owns 14,445 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 4,145 shares during the last quarter. California Public Employees Retirement System grew its position in shares of Amicus Therapeutics by 2.4% during the 3rd quarter. California Public Employees Retirement System now owns 181,000 shares of the biopharmaceutical company’s stock valued at $2,729,000 after acquiring an additional 4,200 shares during the period. Teachers Advisors LLC grew its position in shares of Amicus Therapeutics by 0.9% during the 4th quarter. Teachers Advisors LLC now owns 663,936 shares of the biopharmaceutical company’s stock valued at $9,554,000 after acquiring an additional 5,858 shares during the period. QS Investors LLC grew its position in shares of Amicus Therapeutics by 4.9% during the 4th quarter. QS Investors LLC now owns 159,008 shares of the biopharmaceutical company’s stock valued at $2,288,000 after acquiring an additional 7,483 shares during the period. Finally, Nationwide Fund Advisors grew its position in shares of Amicus Therapeutics by 5.6% during the 3rd quarter. Nationwide Fund Advisors now owns 178,212 shares of the biopharmaceutical company’s stock valued at $2,687,000 after acquiring an additional 9,503 shares during the period.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.